Estrogens medroxyprogesterone

Activella—estradiol, norethindrone acetate CombiFhtch—estradiol, norethindrone Femhrt—ethinyl estradiol, norethindrone acetate Ortho-Pretest—estradiol, norgestimate Premephase—conjugated estrogens, medroxyprogesterone acetate... 

Estrogen/progestogen combinations, oral conjugated estrogens/ medroxyprogesterone ethinyl estradiol/norethindrone acetate mestranol/norethindrone... 

It has long been considered that the risk of endometrial carcinoma may be somewhat reduced by HRT, but that the risk is affected by the dose of progestogen used, if any. In a recent population-based case-control study covering 647 cases and 1209 controls, users of estrogen + medroxyprogesterone acetate (MPA) given for 10-24 days monthly in a dose of 100 mg/month or more showed the same risk of endometrial cancer as women not using HRT... 

Conj Estrogens/ Medroxyprogesterone Prempro Wyeth-Ayerst OBS Hormone replacement therapy... 

Premphase Conjugated estrogens Medroxyprogesterone acetate (cyclic)... 

Retrospective analysis of data from a large randomised, placebo-control-led study of HRT (conjugated estrogens/medroxyprogesterone... 

Health Initiative Memory Study reported that hormone replacement with either estrogen alone or estrogen plus medroxyprogesterone resulted in negative effects on memory.22... 

Utian WH, Shoupe D, Backmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001 75 1065-1079. 

CHCs, even those with less than 35 meg estrogen, can cause small increases in blood pressure (6 to 8 mm Hg) in both normotensive and hypertensive women. In women with hypertension, OCs have been associated with an increased risk of MI and stroke. Use of CHCs is acceptable in women younger than 35 years with well-controlled and monitored hypertension. Hypertensive women with end-organ disease or who smoke should not use CHCs. Progestin-only pills and depot medroxyprogesterone acetate (DMPA) are choices for women with hypertension. 

CEE, conjugated equine estrogens MPA, medroxyprogesterone acetate NETA, norethindrone acetate. 

Low-dose hormone therapy (conjugated equine estrogen 0.45 mg and medroxyprogesterone acetate 1.5 mg/day) has demonstrated equivalent symptom relief and bone density preservation without an increase in endometrial hyperplasia. Whether such lower doses will be safer (cause less venous thromboembolism and breast cancer) remains to be seen. 

Premphase One 0.625 mg conjugated estrogens tablet once daily on days 1 through 14 and one 0.625 mg conjugated estrogen/5 mg medroxyprogesterone tablet taken once daily on days 15 through 28. 

A low dosage of progestin ( mini-pill ) is used, in the form of medroxyprogesterone acetate, which is active at a very low dose. The mini-pill does not inhibit ovulation, but rather interferes with the endometrium and the cervical mucus. The use of this pill prevents most of the side effects of oral contraception, specifically nausea, water retention, and in some cases thrombophlebitis. However, a lower success rate and other frequent side effects have reduced the widespread acceptance of this preparation. Nevertheless, the mini-pill has a role to play in certain specific situations. For example, in an uncommon form of epilepsy called catamenial epilepsy, female patients will experience seizures at particular times during their menstrual cycle, reflecting the fact that seizure focus is stimulated by estrogens but inhibited by progestins. In such women, the mini-pill may afford not only birth control but also improved seizure control. 

---